 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA Taysha, a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system CNS in both rare and large patient populations, today highlighted its strategic priorities and provided a business outlook for 2021. We enter 2021 having built a strong foundation on which to execute our corporate and pipeli 